Phase 2, Randomized Double-Blind Double-Dummy Placebo-Controlled Study Testing the Safety & Efficacy of Semaglutide, & the Fixed-Dose Combination of Cilofexor & Firsocostat, Alone & in Combination, in Subjects with Compensated Cirrhosis (F4) due to NASH

Investigator: David Victor, MD

Study Coordinator: Lindsay Barter

Status: Enrolling

ClinicalTrials.gov Number: NCT04971785

Phone: 502.417.6664

Protocol Number: PRO00033130

Description

The goals of this clinical study are to learn more about the study drugs, semaglutide (SEMA) with the fixed-dose combination (FDC) of cilofexor/firsocostat (CILO/FIR), and understand whether they cause fibrosis improvement and Nonalcoholic Steatohepatitis (NASH) resolution in participants with cirrhosis due to NASH.
More to Explore
Search Clinical Trials
Join a Clinical Trial
Clinical Research Support Services for Investigators
Weill Cornell Medical College Clinical Trials